{"entity":{"id":"befotertinib","kind":"drug","name":"Befotertinib","aka":[],"tldr":"Befotertinib is an oral kinase inhibitor from Betta Pharmaceuticals Co., Ltd., in registered phase 2 trials for non-small-cell lung cancer.","summary":"Befotertinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Betta Pharmaceuticals Co., Ltd., in non-small-cell lung cancer. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Befotertinib","url":"https://clinicaltrials.gov/search?intr=Befotertinib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["betta"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07181499"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral kinase inhibitor","mechanism":"A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/befotertinib/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"betta","kind":"company","name":"Betta Pharmaceuticals","route":"/companies/betta/"}],"trial":[{"id":"nct07181499","kind":"trial","name":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","route":"/trials/nct07181499/"}]}}